News und Analysen
CenterWell Home Health collects 289,000 meals for needy Americans
CenterWell Home Health, one of America’s largest providers of home health, has supplied more than a quarter-million meals in its latest drive to feed people in need in the communities it serves
3 Stocks to Buy Before 2024 That Can Set You Up For Life
You shouldn't have to keep a close eye on your investments. If you find solid stocks to buy, you can leave them in your portfolio and simply wait for their operations to grow and become larger over
Are These 3 Cheap Dividend Stocks With High Yields Too Good to Be True?
When dividend stocks crash in value, that sends their yields up in the opposite direction. But there can be danger for investors who load up on a stock just because its yield is high.
Before buying
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?
Pfizer (NYSE: PFE) was a top performer when the U.S. government was shoveling COVID-related revenue in its direction. Unfortunately, the past year hasn't been nearly as kind. The former high-flying
Why Vertex Stock Is Soaring Today
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are up by more than 11% headed into the latter half of Wednesday's trading session, catapulted higher by the promising results achieved in a mid-stage
Why Pfizer Stock Is Sinking Today
Shares of Pfizer (NYSE: PFE) were sinking 8.3% lower as of 11:25 a.m. ET on Wednesday. The sharp sell-off came after the drugmaker provided its guidance for full-year 2024.
Pfizer expects 2024
1 Biotech Stock That Could Be the Next Amgen
The human genome project, which was completed in 2003, marked a milestone for biotechnology. It opened the door for the creation of hundreds of medicines based on biology, which have improved the
2 Big-Name Stocks Are Falling Wednesday -- Here's Why
The stock market looked ready to keep climbing early Wednesday, even as investors were largely in wait-and-see mode during the last day of the Federal Reserve's current monetary policy meeting
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?
Outperforming the benchmark S&P 500 index over a long period is a formidable challenge. This task becomes even more daunting when choosing stocks from the healthcare sector, where the competitive
AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors
With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the
Humana Earns Top Score in Human Rights Campaign Foundation’s 2023 Corporate Equality Index
Leading US health insurer and health care services company Humana Inc. (NYSE: HUM) has earned a score of 100 percent on the Human Rights Campaign Foundation Corporate Equality Index and the
3 Dirt Cheap Stocks That Make Terrific Buys Before the End of the Year
The stock market has climbed this year, but that doesn't mean the bargains are over. Many stocks missed out on the rally even though their long-term outlooks remain solid. And these are the stocks
Why Cigna Stock Soared Today
Shares of Cigna Group (NYSE: CI) were up 16.6% as of 1:30 p.m. ET Monday after the health insurance giant reportedly called off its potential acquisition Humana and announced a $10 billion buyback
Monday Morning's 2 Must-Watch Stocks
The stock market has been on a tear for more than a month now, and so it's not unreasonable to see major market benchmarks taking a pause coming into a new week. Stock indexes were mostly flat at
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?
Change the narrative: That's been a classic strategy for businesses facing stiff challenges. And it's a strategy that AbbVie (NYSE: ABBV) appears to have pulled off successfully in recent days.
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) has built a billion-dollar cystic fibrosis (CF) treatment empire, but investors have been looking for something more. They've hoped to see the company broaden
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond
One famous investing maxim advises to buy low and sell high. That's sage advice, but not all stocks are worth investing in while they are down. If they don't go up, you won't have profited from the
3 Dividend Stocks Trading at 52-Week Lows
I have always stated that stocks should not be bought just because they trade at a 52-week low. A new 52-week low does not make a particular stock cheap.
In today's video I will look at three
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years
While some stocks may not be attracting quite the same hype they were a few years ago, that doesn't mean the quality of their underlying businesses has evaporated. If your intention is to own great
Is Pfizer Stock a Buy Now?
Shares of Pfizer (NYSE: PFE) have been in an endless tailspin this year -- now down more than 40%. The top drugmaker can't seem to catch a break. Revenue from its COVID-19 products is down big, and
3 Dividend Stocks You Can Safely Hold for Decades
Remember Montgomery Ward, Lehman Brothers, and Pan Am? They were all well-known publicly traded companies that paid dividends. And they all went out of business.
Investors who bought those stocks
Better Dividend Stock: AbbVie vs. Medical Properties Trust
Income-seeking investors have some interesting options to choose from in the healthcare sector right now. AbbVie (NYSE: ABBV), the pharmaceutical giant behind the top-selling drug of the past
Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not
2 Healthcare Stocks to Buy Hand Over Fist in December
As the year draws to a close, it's as good a time as any to review one's investments and consider adding more money into the stock market. The goal shouldn't be to take advantage of the January
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
As reported by Fierce Biotech on Nov. 22, gene-therapy star CRISPR Therapeutics (NASDAQ: CRSP) laid off 10% of its employees shortly after reporting its Q3 earnings earlier in the month. Given that